Table 1.
Clinical characteristics of patients with AML by p53 protein expression patterns
| Characteristics | Mutant p53 expression pattern* | wt p53 expression pattern† | |||
|---|---|---|---|---|---|
| p53high (n = 93) | p53truncated (n = 34) | p53wt (n = 84) | P * | P † | |
| Age | 66.7 (21.7-86.9) | 66.9 (17.9-87.4) | 64.1 (18.7-89.0) | .613 | .274 |
| Age >60 y | 23 (24.7%) | 12 (35.3%) | 29 (34.5%) | .238 | .281 |
| Sex (Male) | 48 (51.6%) | 17 (50%) | 50 (59.5%) | .872 | .234 |
| Race | .539 | .136 | |||
| White | 66 | 20 | 60 | ||
| Black | 11 | 6 | 8 | ||
| Hispanic | 5 | 1 | 9 | ||
| Asian | 6 | 3 | 1 | ||
| Other | 5 | 4 | 6 | ||
| Blast count (range) | 38 (20-98%) | 42 (20-88%) | 57 (20-97%) | .671 | .001 |
| White blood count | 2.9 (0.1-171.6) | 5.1 (0.3-51.8) | 7.3 (0.8-251.1) | .283 | .002 |
| Serum lactate dehydrogenase | 561 (144-12 593) | 767 (220-10 721) | 348 (118-3083) | .015 | <.001 |
| Mutation type | <.001 | <.001 | |||
| Missense | 71 | 1 | 6 | ||
| Nonsense | 4 | 13 | 1 | ||
| Frameshift | 3 | 13 | 0 | ||
| Deletion | 3 | 0 | 0 | ||
| Splice site | 5 | 7 | 0 | ||
| Not applicable (wt) | 7 | 0 | 0 | ||
| Median TP53 VAF (range) | 47.4 (1.0-97.3%) | 54.3 (2.0-94.2%) | 43.75 (2.6-95.4%) | .570 | .933 |
| Mutation location (domains) | .001 | <.001 | |||
| TAD (1−44) | 0 | 1 | 0 | ||
| TAD2 (35−59) | 0 | 1 | 0 | ||
| DBD (109−288) | 78 | 21 | 7 | ||
| TETRAMER (319−355) | 2 | 0 | 1 | ||
| Other | 1 | 4 | 0 | ||
| Splicing site | 5 | 7 | 0 | ||
| Cytogenetic risk group | .504 | <.001 | |||
| Adverse | 85 | 33 | 19 | ||
| Intermediate | 5 | 0 | 57 | ||
| Favorable | 1 | 0 | 6 | ||
| Complex karyotype | 79 | 33 | 5 | .095 | <.001 |
| Del(5q)/-5 & del(7q)/-7 | 69 | 26 | 13 | n/a | n/a |
| Normal karyotype | 4 | 0 | 48 | n/a | n/a |
| TP53 mutation & allelic state | .415 | <.001 | |||
| wt & normal CN | 7 | 0 | 76 | ||
| 1 mutation & CNloss | 42 | 19 | 3 | ||
| 1 mutation & normal CN | 10 | 5 | 4 | ||
| >1 mutation & CNloss | 6 | 2 | 0 | ||
| >1 mutation & normal CN | 4 | 0 | 0 | ||
| TP53 CN loss | 48/69 | 21/26 | 3/83 | .275 | <.001 |
| Primary vs secondary AML | .690 | .001 | |||
| Primary | 65 | 25 | 6 | ||
| Secondary‡ | 28 | 9 | 1 | ||
| AML WHO category | .560 | <.001 | |||
| AML-MRC | 59 | 25 | 22 | ||
| t-AML | 24 | 7 | 6 | ||
| AMLpMPN | 4 | 2 | 2 | ||
| AML with recurrent genetic alterations | 5 | 0 | 38 | ||
| AML not otherwise specified | 1 | 0 | 16 | ||
| Treatment status | .720 | <.001 | |||
| FL | 51 | 17 | 77 | ||
| Secondary FL | 16 | 8 | 3 | ||
| Salvage | 26 | 9 | 4 | ||
| Venetoclax-based therapy | 26/76 (34.2%) | 10/25 (40%) | 52/70 (74.3%) | .600 | <.001 |
| Therapy intensity | .567 | .149 | |||
| High | 24 | 7 | 31 | ||
| Low | 52 | 18 | 39 | ||
| Stem cell transplant | 6 | 2 | 8 | n/a | n/a |
| Best response | <.001 | ||||
| Complete remission | 18 | 7 | 44 | ||
| Incomplete remission (CRi) | 11 | 3 | 10 | ||
| No response | 34 | 7 | 4 | ||
| Measurable residual disease | 18/28 | 5/7 | 0/2 | .722 | n/a |
Categorical variables are compared using Pearson χ2 test or Fisher's exact test. Continuous variables between patient groups are compared using the Mann-Whitney U test.
n/a, not applicable; TAD, transactivation domain; wt, wild-type.
*
Comparison between p53high and p53truncated.
†
Comparison between p53mutant (p53high+p53truncated) vs p53wt.
‡
Includes AML arising after antecedent hematologic neoplasm and t-AML.
Boldface highlights significant P values.